These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25595667)

  • 1. Reduced serum chemerin in patients with more severe liver cirrhosis.
    Eisinger K; Krautbauer S; Wiest R; Weiss TS; Buechler C
    Exp Mol Pathol; 2015 Apr; 98(2):208-13. PubMed ID: 25595667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension.
    Eisinger K; Krautbauer S; Wiest R; Karrasch T; Hader Y; Scherer MN; Farkas S; Aslanidis C; Buechler C
    Eur J Clin Invest; 2013 Sep; 43(9):926-32. PubMed ID: 23855493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis.
    Horn P; von Loeffelholz C; Forkert F; Stengel S; Reuken P; Aschenbach R; Stallmach A; Bruns T
    Sci Rep; 2018 Jun; 8(1):9242. PubMed ID: 29915268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.
    Weigert J; Neumeier M; Wanninger J; Filarsky M; Bauer S; Wiest R; Farkas S; Scherer MN; Schäffler A; Aslanidis C; Schölmerich J; Buechler C
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):342-8. PubMed ID: 19558533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury.
    Bauer S; Eisinger K; Wiest R; Karrasch T; Scherer MN; Farkas S; Aslanidis C; Buechler C
    Regul Pept; 2012 Nov; 179(1-3):10-4. PubMed ID: 22960408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
    Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
    Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis.
    Wiest R; Weigert J; Wanninger J; Neumeier M; Bauer S; Schmidhofer S; Farkas S; Scherer MN; Schäffler A; Schölmerich J; Buechler C
    Cytokine; 2011 Feb; 53(2):178-83. PubMed ID: 20637651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
    Feder S; Wiest R; Weiss TS; Aslanidis C; Schacherer D; Krautbauer S; Liebisch G; Buechler C
    Lipids Health Dis; 2021 Jan; 20(1):6. PubMed ID: 33461570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function.
    Wanninger J; Weigert J; Wiest R; Bauer S; Karrasch T; Farkas S; Scherer MN; Walter R; Weiss TS; Hellerbrand C; Neumeier M; Schäffler A; Buechler C
    Cytokine; 2011 Sep; 55(3):435-40. PubMed ID: 21715185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipokines in Liver Cirrhosis.
    Buechler C; Haberl EM; Rein-Fischboeck L; Aslanidis C
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28661458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis.
    Krautbauer S; Eisinger K; Wiest R; Liebisch G; Buechler C
    Prostaglandins Other Lipid Mediat; 2016 Jul; 124():27-33. PubMed ID: 27265202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis.
    Juanola O; Ferrusquía-Acosta J; García-Villalba R; Zapater P; Magaz M; Marín A; Olivas P; Baiges A; Bellot P; Turon F; Hernández-Gea V; González-Navajas JM; Tomás-Barberán FA; García-Pagán JC; Francés R
    FASEB J; 2019 Oct; 33(10):11595-11605. PubMed ID: 31345057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study.
    Wiest R; Weiss TS; Danielyan L; Buechler C
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34204545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
    Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
    Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites.
    Martinet JP; Legault L; Cernacek P; Roy L; Dufresne MP; Spahr L; Fenyves D; Pomier-Layrargues G
    J Hepatol; 1996 Nov; 25(5):700-6. PubMed ID: 8938548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Ferritin in Patients With Cirrhosis is Associated With Markers of Liver Insufficiency and Circulatory Dysfunction, but Not of Portal Hypertension.
    Ripoll C; Keitel F; Hollenbach M; Greinert R; Zipprich A
    J Clin Gastroenterol; 2015 Oct; 49(9):784-9. PubMed ID: 25599219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients.
    Feder S; Haberl EM; Spirk M; Weiss TS; Wiest R; Buechler C
    Clin Exp Med; 2020 May; 20(2):289-297. PubMed ID: 32078718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.